Skip to Content


Treatment for Diabetes Type 1, Diabetes Type 2

Pfizer and sanofi-aventis Statement on Status of Exubera

NEW YORK, October 28, 2005 -- Pfizer and sanofi-aventis, a member of the sanofi-aventis Group, said today that the U.S. Food and Drug Administration has notified the companies that it is extending its original review period for Exubera (insulin (rDNA origin) powder for oral inhalation) by three months to review additional technical chemistry data submitted by the companies.

In September, an FDA Advisory Committee recommended approval of Exubera for the treatment of adults with type 1 and type 2 diabetes. FDA is not obligated to follow the Advisory Committee's recommendation, but usually does so. Pfizer and sanofi-aventis continue to work closely with the FDA so that this important medicine can be made available for patients.

Source: Pfizer

Posted: October 2005

Related Articles

Exubera (insulin inhalation) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.